Ascentage Pharma Group International (AAPG) stock
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
Ascentage Pharma Group International saw revenue fall 41.5% to CN¥574.12M over fiscal 2025. Free cash flow was -CN¥1.20B. At the latest close the market valued the company at CN¥9.11B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- CN¥9.11B
- P/E ratio
- –
- Price to sales
- 15.87
- Price to book
- 6.88
- Dividend yield
- –
- Free cash flow yield
- -13.19%
Fundamentals
- Revenue
- CN¥574.12M
- Net income
- -CN¥1.24B
- EPS, diluted
- -3.49 CNY
- Free cash flow
- -CN¥1.20B
Trading
- Previous close
- $15.02
- Open
- $14.69
- Day's range
- $14.62 – $14.89
- Volume
- 8,735
- Average volume (20 days)
- 7,555
- RSI (14 days)
- 45.3
- Volatility (1 year)
- 61.1%
- Relative volume
- 1.29×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | AAPG | S&P 500 | Difference | AAPG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.9% | -3.0% | +0.1 pts | ||
| 3 months | -23.1% | -2.8% | −20.3 pts | ||
| Year to date | -44.3% | +11.5% | −55.8 pts | ||
| 1 year | -56.6% | +13.5% | −70.0 pts |
Five years at a glance
Fiscal years 2021 to 2025, CNY
Revenue
Gross profit
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ascentage Pharma Group International filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Ascentage Pharma Group International
Pharmaceutical Preparations
Ascentage Pharma Group International is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and pharmaceutical products. The company develops clinical and preclinical drug candidates, with primary commercial products including Olverembatinib and Lisaftoclax. Its operations center on pharmaceutical product sales, commercialization rights agreements, intellectual property licensing, and management services. The company provides its pharmaceutical products to patients needing medical treatment, while also collaborating with and serving biopharmaceutical industry partners such as Innovent and Takeda.
Company profile, executives and historyAscentage Pharma Group International stock: common questions
What is Ascentage Pharma Group International's stock price?
AAPG closed at $14.62 on Nov 13, 2026, down 2.66% on the day.
What is Ascentage Pharma Group International's market cap?
Ascentage Pharma Group International was worth $1.36B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is AAPG's P/E ratio?
Ascentage Pharma Group International lost money over fiscal 2025 (diluted EPS -3.49 CNY), so it has no meaningful P/E ratio.
How much revenue does Ascentage Pharma Group International make?
Ascentage Pharma Group International reported revenue of CN¥574.12M for fiscal 2025, down 41.5% from a year earlier.
Does Ascentage Pharma Group International pay a dividend?
No. Ascentage Pharma Group International has not paid a cash dividend over the last twelve months.
How has AAPG stock performed over the past year?
Including dividends, AAPG returned -56.6% over the past year, against +13.5% for the S&P 500.
Who are Ascentage Pharma Group International's competitors?
Companies most similar to Ascentage Pharma Group International by business, industry and size include HCM, RARE, ZLAB, PTGX, LGND.
See a number that looks wrong?